Trials / Completed
CompletedNCT02069041
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Phase 1b Study of 5-FU/FA and Oxaliplatin (FOLFOX4) Plus Ramucirumab (LY3009806) in Patients With Advanced Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine if the advised dose of ramucirumab is safe to be taken with chemotherapy treatment in participants with advanced liver tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ramucirumab | Administered IV. |
| DRUG | FOLFOX4 | Administered IV. |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2014-02-21
- Last updated
- 2018-11-21
- Results posted
- 2018-11-21
Locations
3 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT02069041. Inclusion in this directory is not an endorsement.